The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis

To perform a meta-analysis of prospective, two-arm studies examining the clinical utility of using the combinatorial pharmacogenomic test, GeneSight Psychotropic, to inform treatment decisions for patients with major depressive disorder (MDD). The pooled mean effect of symptom improvement and pooled...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmacogenomics 2020-06, Vol.21 (8), p.559-569
Hauptverfasser:	Brown, Lisa, Vranjkovic, Oliver, Li, James, Yu, Kunbo, Al Habbab, Talal, Johnson, Holly, Brown, Krystal, Jablonski, Michael R, Dechairo, Bryan
Format:	Artikel
Sprache:	eng
Schlagworte:	Antidepressive Agents - adverse effects Antidepressive Agents - therapeutic use clinical utility combinatorial pharmacogenomics depression Depressive Disorder, Major - drug therapy Depressive Disorder, Major - epidemiology Depressive Disorder, Major - genetics GeneSight Humans major depressive disorder meta-analysis Pharmacogenomic Testing - methods Prospective Studies Psychotropic Drugs - adverse effects Psychotropic Drugs - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!